Clovis Oncology, Inc. (Nasdaq: CLVS) announced today that the first clinical study of CO-1686 has commenced with the dosing of the first patient at a U.S. study site. CO-1686 is a novel, oral, targeted covalent inhibitor of epidermal growth factor receptor (EGFR) mutations currently being studied for the treatment of non-small cell lung cancer (NSCLC).
The dose escalation portion of the Phase I/II study is being conducted at 5 sites in the U.S. and Europe, and the Company intends to initiate a parallel Phase I/II study in Asia during the third quarter of 2012. Following the establishment of the appropriate dose, Clovis intends to study CO-1686 in an expansion cohort of NSCLC patients who have failed EGFR-directed therapy, such as Tarceva ® or Iressa ®, and have developed the T790M mutation, which is the dominant resistance mechanism to Tarceva and Iressa. Clovis is developing a companion diagnostic in collaboration with Roche Molecular Systems, Inc. to identify patients with the T790M mutation.
“While the development of EGFR tyrosine kinase inhibitor therapy for NSCLC patients with EGFR mutations has been a major advance, resistance develops after about a year and is a major obstacle lung oncologists face in the clinic each day,” said Lecia Sequist, Thoracic Medical Oncologist at Massachusetts General Cancer Center, Assistant Professor of Medicine at Harvard Medical School and an investigator in the study. “At the current time, there are no approved standard treatments available for patients with the T790M resistance mutation. Better solutions to this problem are desperately needed.”
“CO-1686 is the first covalent inhibitor to enter the clinic designed to target both the activating mutations of EGFR and the resistance mutation T790M, and we are committed to working with our investigators to rapidly develop this compound,” said Patrick J. Mahaffy, president and CEO of Clovis Oncology. “As has been presented at scientific meetings, CO-1686 is highly potent against these mutations of EGFR, including T790M, while sparing wild-type EGFR, and we are pleased to seek confirmation of these characteristics in patients.”
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV